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Background: Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit
the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm
of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-
QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype.
Methods: The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A
clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was
made by clinicians at enrollment. Baseline early-morning, day-time and nocturnal symptoms (gathered via the
Night-time, Morning and Day-time Symptoms of COPD questionnaire), HR-QoL (via the St. George’s Respiratory
Questionnaire), anxiety and depression levels (via the Hospital Anxiety and Depression Scale), quality of sleep (via
COPD and Asthma Sleep Impact Scale), physical activity (via the International Physical Activity Questionnaire) as well as
lung function were recorded.
Results: 606 COPD subjects (age 71.4 ± 8.2 years, male 75.1%) were studied. 57.9, 35.5 5.3 and 1.3% of the sample
belonged to the CB, EM, MCA and EM + CB phenotypes respectively. The vast majority of subjects reported early-
morning and day-time symptoms (79.5 and 79.2% in the CB and 75.8 and 77.7% in the EM groups); the proportion
suffering from night-time symptoms was higher in the CB than in the EM group (53.6% vs. 39.5%, p = 0.0016). In
both CB and EM, indiscriminately, the presence of symptoms during the 24-h day was associated with poorer HR-
QoL, worse quality of sleep and higher levels of anxiety/depression.
Conclusions: The findings highlight the primary classificatory role of nocturnal symptoms in COPD.
Trial registration: Trial registration number: NCT03105999, date of registration: 10th April 2017.
Keywords: 24-hour symptoms, Clinical phenotype, Respiratory function, Real-worldBackground
Chronic Obstructive Pulmonary Disease (COPD) is a com-
mon, preventable condition characterized by persistent air-
flow limitation, initiated and sustained by chronic exposure
to smoke and other irritants [1]. The complexity and the
heterogeneous clinical presentation of the disease, however,
requires a more comprehensive approach, obliging physi-
cians to take account of symptoms and exacerbations, and
to manage the concomitant occurrence of extra-pulmonary© The Author(s). 2019 Open Access This artic
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rows and Fletcher’s original proposal of emphysematous
and bronchitic phenotypes [2] is no longer sufficient to
identify the different clinical forms of the disease in clinical
practice. A COPD phenotype is considered to be a set of at-
tributes that can help differentiate patients on the basis of
clinically meaningful parameters, such as symptoms, exac-
erbations, progression of disease decline, physical inactivity,
response to treatment, and mortality.
One effort to classify COPD individuals according to
their clinical presentations is the Spanish COPD guide-
lines [3], which distinguish the emphysema from thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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of exacerbations. In addition, a mixed COPD-asthma
phenotype (asthma-COPD overlap [ACO]) has been pro-
posed, although its interpretation and association with
exacerbation and mortality are now controversial [4–6].
Distinguishing the bronchitic from the emphysematous
phenotype is apparently an easy task. The former is
marked by productive cough and early onset of hypox-
emia, with high prevalence of respiratory failure and
chronic cor pulmonale, whereas the latter displays early
and severe dyspnea with late-onset hypoxemia. Hypo-
thetically, these clinical presentations could benefit se-
lectively by the treatment options available, but, in real
life settings the spectrum of therapies is variably distrib-
uted across the range of severity of COPD, without any
distinction in terms of phenotypes, thus making such
personalized care treatment more difficult.
Taken together, these observations show the need for
deeper understanding of the clinical phenotypes of COPD.
The STORICO study (STudio Osservazionale sulla carat-
teRizzazione dei sIntomi delle 24 ore nei pazienti con
broncopneumopatia cronica ostruttiva, Observational
study on characterization of 24-h symptoms in patients
with COPD) offers a unique opportunity to analyze the
clinical characteristics of subjects with COPD in relation
to the 24-h day-long variability of symptoms. For example,
given that dyspnea depends mainly on physical effort, it is
logical to expect this symptom to be far more evident dur-
ing daytime, and in EM subjects.
To reinforce the classical phenotyping strategy, this paper
aims primarily to assess, within the clinical COPD pheno-
types, the circadian rhythm of COPD symptoms at baseline
(in terms of frequency of early-morning, day-time and
night-time symptoms). As secondary objective, for each clin-
ical phenotype, we investigated the potential association at
enrollment of the circadian variability of symptoms with
both disease severity and selected indicators of health status.
Method
Study design
STORICO (NCT03105999) is an Italian, multicenter ob-
servational prospective cohort study conducted in 40
pulmonology referral care centers. The enrollment
started in February 2016 and the 1-year longitudinal
phase of the study ended in June 2018; a total of three
visits (baseline and follow-up at 6-month intervals) were
performed. The present paper reports the results of the
cross-sectional phase. More details about the STORICO
study are available elsewhere [7].
Subjects
Subjects of both sexes aged ≥50, current or former smokers
with a smoking history of at least 10 pack-years, with a
diagnosis of COPD and in stable conditions for at least 12months according to GOLD 2014 [8] were enrolled con-
secutively. Patients provided written, informed consent be-
fore participation. Patients participating in a clinical trial
and those who had changed their COPD treatment regi-
men in the 3months prior to enrolment were excluded, as
were patients with recent exacerbations (within 1month
prior to enrollment). Also, patients under continuous use
of oxygen therapy or suffering from asthma, sleep apnea
syndrome or other chronic diseases that reduced life ex-
pectancy to less than 3 years (Charlson index> 3) were ex-
cluded. Among enrolled patients, only those with available
information on the frequency of COPD symptoms during
each part of the 24-h day were analyzed.
The sample size was determined by criteria of feasibility.
In fact, given the volume of patients handled by the centers
involved in the study, inclusion of approximately 600 sub-
jects with the characteristics defined by the Inclusion/Ex-
clusion criteria was deemed reasonable. An evaluation of
the possible precision of the estimates was performed in
consideration of the primary objectives, finding that a sam-
ple of 100 patients per group (i.e. per class of phenotype)
would allow precise estimates of the expected proportion of
COPD symptoms ≥30%. More details concerning sample
size justification are provided elsewhere [7].Clinical assessment
On the first assessment day, anthropometric data and
clinical history were collected and each subject was
assigned a clinical COPD phenotype based on the judg-
ment of the clinician: chronic bronchitis (CB), defined as
the presence of productive cough for at least 3 months
in two consecutive years; emphysema (EM), for patients
whose predominant symptoms are dyspnea and reduced
tolerance to exercise; mixed COPD-asthma (MCA) for
patients with documented not completely reversible air-
flow obstruction, accompanied by symptoms or signs of
obstruction reversibility [9, 10]. As part of the investiga-
tion, local researchers were asked to express their degree
of confidence in the choice of clinical phenotype on a
scale of 0 to 10, from no confidence at all to maximum
of confidence. Disease severity was defined using the
combined COPD assessment according to GOLD [11].
Spirometry was performed according to the recommen-
dations of the American Thoracic Society (ATS) and the
European Respiratory Society (ERS); forced expiratory
volume in the first second (FEV1) and forced vital cap-
acity (FVC) were retained for analysis. Although not
mandatory by protocol, the centers were invited to rec-
ord static lung volumes, and Residual Volume (RV) and
Total Lung Capacity (TLC) were obtained together with
diffusion capacity for carbon monoxide (DLCO), in
order to support the clinical assignment of subjects to
the phenotypes.
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According to the study design, subjects completed the
Night-time, Morning and Day-time Symptoms of COPD
questionnaire [12]). This is a 33-item questionnaire devel-
oped by Almirall S.A., Barcelona, Spain covering the fre-
quency and severity of COPD symptoms (breathlessness,
coughing, bringing up phlegm or mucus, chest tightness,
chest congestion and wheezing) during each part of the
day. This represented the primary outcome of the study.
The questionnaire includes 13 symptom items for
night-time (i.e. the time between going to bed and getting
up), 10 symptom items for early-morning (i.e. the time
from getting up until approximately 11:00 am) and 10
symptom items for day-time (i.e. from approximately 11:
00 am until the subject goes to bed).
To address the secondary outcomes of the study the fol-
lowing measures were performed: the level of perceived
breathlessness and the extent to which it affected mobility
were assessed by the modified Medical Research Council
(mMRC) dyspnea scale ranging from 0 (breathless with
strenuous exercise) to 4 (too breathless to leave the house
or breathless when dressing or undressing) [13]; health-
related quality of life (HR-QoL) was evaluated by the St.
George’s Respiratory Questionnaire (SGRQ), including the
subject’s perception of recent respiratory problems (Symp-
toms component), disturbances to daily physical activity
(Activity component) and disturbances of psycho-social
function (Impact component); a total score was also calcu-
lated. Scores range from 0 (no impairment) to 100 (highest
impairment) [14–17], anxiety and depression states were
investigated through the Hospital Anxiety and DepressionFig. 1 Patients enrolled and included in the analyses. CB: Chronic BronchitScale (HADS) [18–20], with a total score (emotional dis-
tress) ranging from 0 to 42; anxiety and depression subscale
scores (range 0–21) were also computed, higher scores in-
dicating more distress; the impact of respiratory symptoms
on sleep was assessed by the COPD and Asthma Sleep Im-
pact Scale (CASIS) [21], a self-administered, 7-item scale.
The total score range is 0–100, with higher scores indicat-
ing greater sleep impairment in the previous week; physical
activity was assessed with the International Physical Activ-
ity Questionnaire (IPAQ) [22, 23] and a categorical score
(low, medium, high level of physical activity) was
calculated.
The presence of relevant comorbidities and the number
of exacerbations/year in the 5 years before enrollment
were recorded. In particular, the presence of anemia was
defined as hemoglobin < 13.5 g/dl (for males) and < 12 g/dl
(for females), and an estimated glomerular filtration rate
(eGFR) < 60mL/min/1.73m2 was considered as indicator
of chronic kidney disease [24]. The eGFR was calculated
according to the equation proposed by the Chronic Kid-
ney Disease Epidemiology Collaboration [25].Statistical analysis
Descriptive statistics were calculated both overall and within
each phenotype: mean and standard deviation (SD), median,
interquartile range (IQR) for quantitative variables and abso-
lute and relative frequency for categorical variables.
Missing values were not replaced and did not contrib-
ute to the analysis of the variable. Frequencies of missing
data were given for all analyzed variables.is; MCA: Mixed-COPD asthma
Table 1 Socio-demographic, clinical and biological characteristics of the subjects
Overall (N = 606) CB (N = 351) EM (N = 215) MCA (N = 32)
Age (yrs) (mean ± SD) 71.4 ± 8.2 71.6 ± 8.3 71.5 ± 7.9 70.1 ± 8.2
Males (N, %) 455 (75.1) 256 (72.9) 174 (80.9) 20 (62.5)
Education (N, %)
None 4 (0.7) 3 (0.9) 0 0
Primary school 173 (29.6) 111 (32.8) 54 (25.7) 7 (22.6)
Middle school 241 (41.2) 127 (37.6) 93 (44.3) 19 (61.3)
High school 133 (22.7) 76 (22.5) 51 (24.3) 4 (12.9)
University 34 (5.8) 21 (6.2) 12 (5.7) 1 (3.2)
NK 21 13 5 1
Occupational status (N, %)
Unemployed 23 (3.8) 16 (4.6) 5 (2.4) 2 (6.5)
Employed 77 (12.8) 44 (12.6) 25 (11.7) 5 (16.1)
Retired 468 (77.9) 265 (75.9) 176 (82.6) 22 (71.0)
Housewife/househusband 33 (5.5) 24 (6.9) 7 (3.3) 2 (6.5)
NK 5 2 2 1
Smoking status (N, %)
Former smoker 445 (73.4) 250 (71.2) 166 (77.2) 25 (78.1)
Current smoker 161 (26.6) 101 (28.8) 49 (22.8) 7 (21.9)
Estimated amount of tobacco consumed (pack/year) (median IQR) 39.0 (20.0–50.0) 35.0 (20.0–52.0) 40.0 (23.0–50.0) 30.0 (20.0–45.0)
Smoking duration (yrs) (median IQR) 40.0 (30.0–49.5) 40.0 (30.0–50.0) 40.0 (32.0–50.0) 39.0 (30.0–42.0)
BMI (N, %)
Underweight (BMI < 18.5) 13 (2.2) 4 (1.2) 9 (4.2) 0
Normal weight (BMI 18.5–24.9) 183 (30.5) 90 (26.0) 81 (37.9) 11 (34.4)
Overweight (BMI 25–29.9) 272 (45.3) 163 (47.1) 91 (42.5) 16 (50.0)
Obese (BMI ≥30) 132 (22.0) 89 (25.7) 33 (15.4) 5 (15.6)
NK 6 5 1 0
Comorbidities (N, %)
≥ 1 comorbidity 446 (73.6) 254 (72.4) 163 (75.8) 23 (71.9)
Anemiaa 36 (26.7) 26 (33.8) 8 (16.0) 2 (33.3)
Arterial Hypertension 308 (50.8) 188 (53.6) 97 (45.1) 17 (53.1)
Atrial fibrillation 34 (5.6) 20 (5.7) 12 (5.6) 2 (6.3)
Cardiac ischemic disease 63 (10.4) 35 (10.0) 21 (9.8) 6 (18.8)
Diabetes 65 (10.7) 40 (11.4) 20 (9.3) 4 (12.5)
GERD 24 (4.0) 14 (4.0) 8 (3.7) 2 (6.3)
Neoplastic disease 31 (5.1) 10 (2.8) 17 (7.9) 3 (9.4)
Osteoporosis 26 (4.3) 19 (5.4) 5 (2.3) 1 (3.1)
Blood tests
eGFR < 60 mL/min/1.73 m2 (N, %) n = 122 n = 65 n = 49 n = 6
17 (13.9) 11 (16.9) 4 (8.2) 2 (33.3)
Hemoglobin (g/dl) (mean ± SD) n = 135 n = 77 n = 50 n = 6
14.0 ± 1.7 13.8 ± 1.8 14.4 ± 1.4 13.2 ± 1.1
Mean cell volume (fl) (mean ± SD) n = 106 n = 64 n = 35 n = 6
90.8 ± 7.9 90.4 ± 7.7 91.2 ± 7.7 93.0 ± 11.4
Eosinophil count (n/mm3) (median IQR) n = 129 n = 75 n = 47 n = 6
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Table 1 Socio-demographic, clinical and biological characteristics of the subjects (Continued)
Overall (N = 606) CB (N = 351) EM (N = 215) MCA (N = 32)
2.3 (0.1–166.0) 3.0 (0.1–190.0) 4.0 (0.1–166.0) 0.1 (0.0–0.1)
Serum creatinine (mg/dL) (median IQR) n = 122 n = 65 n = 49 n = 6
0.9 (0.7–1.1) 0.9 (0.8–1.1) 0.8 (0.7–1.0) 0.8 (0.7–1.2)
Ongoing therapies for COPD (N, %)
≥ 1 525 (86.6) 311 (88.6) 183 (85.1) 27 (84.4)
Triple therapy (LABA, LAMA, ICS) 187 (30.9) 116 (33.0) 62 (28.8) 7 (21.9)
LABA+LAMA 143 (23.6) 58 (16.5) 75 (34.9) 8 (25.0)
LAMA Alone 90 (14.9) 66 (18.8) 23 (10.7) 1 (3.1)
ICS + LABA 78 (12.9) 53 (15.1) 17 (7.9) 8 (25.0)
LABA Alone 18 (3.0) 12 (3.4) 4 (1.9) 2 (6.3)
Other 9 (1.5) 6 (1.7) 2 (0.9) 1 (3.1)
Data about EM + CB not shown
BMI body mass index. CB Chronic Bronchitis. eGFR estimated glomerular filtration rate. EM Emphysema. GERD Gastroesophageal Reflux Disease. ICS Inhaled
corticosteroids. IQR interquartile range. LABA long-acting beta-agonist. LAMA long-acting muscarinic antagonists. MCA Mixed-COPD asthma. NK Unknown. SD
standard deviation; Triple therapy includes any combination of LABA, LAMA, ICS
aPresence of anemia was evaluated for 135 patients in the total sample, 77 CB, 50 EM, 6 MCA
Percentages computed out of non-missing responses
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The frequency of COPD symptoms at enrolment was
calculated overall and within each class of phenotype as
the ratio between the number of patients with at least 1
(early-morning, day-time and night-time) symptom in
the week before enrollment and the total number of eva-
luable patients in the class. Among the symptomatic pa-
tients, the proportion suffering from mild, moderate,
severe and very severe symptoms in the week before en-
rollment was also calculated (overall and by clinical
phenotype). The 95% confidence intervals for the pro-
portions were provided when relevant.Secondary objective
The association between the circadian variability of COPD
symptoms and disease severity at enrollment was evaluated
by calculating the frequency of patients with early-morning,
day-time and night-time symptoms in the groups of patients
according to disease severity (groups A to D of Global Initia-
tive for Chronic Obstructive lung Disease (GOLD)2014
combined assessment). HR-QoL (SGRQ scores), quality of
sleep (CASIS score), anxiety and depression (HADS scores),
level of physical activity (IPAQ categorical score) at enroll-
ment in patients with vs without early-morning, day-time
and night-time symptoms were described and compared
using T-test and Chi-square or Fisher exact test (in the case
of non-parametric distribution). The significance threshold
was adjusted for multiple comparisons (Bonferroni correc-
tion applied) and set to 0.0005 (0.05/number of tests). Site
monitoring, data management and statistical analysis were
performed by MediNeos an IQVIA Company (Modena,
Italy). Statistical analysis was performed using SAS v9.4 andEnterprise Guide v7.1. More details about the STORICO
methodology are available elsewhere [7].
Results
Subject characteristics
Among the 683 COPD individuals enrolled in the STOR-
ICO study, 606 (88.7%) subjects (age 71.4 ± 8.2 years, 75.1%
males) were deemed eligible for the analysis at enrollment;
violations causing exclusion are shown in Fig. 1. A total of
351 subjects (57.9%) were classified as CB, 215 (35.5%) as
EM and 32 (5.3%) as MCA. In addition, 8 subjects (1.3%)
were classified as EM+CB and not retained for analysis due
to the paucity of data. When asked for their level of confi-
dence in attributing the phenotype, the vast majority of phy-
sicians (77.0% CB, 78.4% EM, 58.6% MCA) rated it at least
≥6 out of 10. Baseline socio-demographic and clinical char-
acteristics (including ongoing therapies for COPD) for each
clinical phenotype are shown in Table 1. Table 2 describes
the clinical and functional characteristics of subjects accord-
ing to phenotype. By comparison with EM phenotype, CB
patients were more commonly overweight and had more ex-
acerbations/year in the 5 years before baseline (median
(IQR): 2 [1–4] in CB vs. 1 (0–2) in EM). As shown in
Table 3, the SGRQ components and the total score were
similar across phenotypes and, similarly, the CASIS score
and the HADS scores did not differ between groups. On the
other hand, low levels of physical activity were observed for
35.4% of CB and 18.1% of EM subjects.
Circadian rhythm of symptoms in the clinical COPD
phenotypes
A higher proportion of patients suffered from respiratory
symptoms in the early-morning and day-time (79.5 and
Table 2 COPD medical history, lung function parameters and mMRC Scale score at enrollment
Overall
(N = 606)
CB
(N = 351)
EM
(N = 215)
MCA
(N = 32)
COPD duration (yrs) (mean ± SD) 7.8 ± 6.5 7.7 ± 6.5 8.0 ± 6.3 8.7 ± 8.9
Age at COPD diagnosis (yrs) (mean ± SD) 63.6 ± 9.1 63.9 ± 9.4 63.5 ± 8.1 61.4 ± 11.5
N of COPD exacerbations/year (5 years before baseline) median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–4.0) 1.0 (0.0–2.0) 3.0 (1.0–5.0)
COPD assessment (GOLD guidelines) (N, %)
group A 155 (25.6) 76 (21.7) 66 (30.7) 12 (37.5)
group B 187 (30.9) 133 (37.9) 43 (20.0) 7 (21.9)
group C 126 (20.8) 59 (16.8) 57 (26.5) 8 (25.0)
group D 138 (22.8) 83 (23.6) 49 (22.8) 5 (15.6)
FEV1 (L)
Median (IQR)
n = 535 n = 298 n = 200 n = 29
1.5 (1.2–2.0) 1.6 (1.2–2.0) 1.5 (1.1–2.0) 1.5 (1.2–1.9)
FEV1 of the predicted (%)
Median (IQR)
n = 537 n = 300 n = 200 n = 29
63.9 (50.0–80.0) 66.9 (51.0–81.8) 61.9 (48.1–78.0) 58.4 (48.3–77.2)
FVC (L)
Median (IQR)
n = 536 n = 299 n = 200 n = 29
2.7 (2.2–3.4) 2.6 (2.2–3.3) 2.9 (2.2–3.5) 2.5 (2.1–3.1)
FEV1/FVC (%)
Median (IQR)
n = 537 n = 300 n = 200 n = 29
59.7 (49.0–69.0) 62.0 (52.0–70.0) 56.0 (45.0–66.6) 62.3 (53.0–68.1)
RV (L)
Median (IQR)
n = 291 n = 130 n = 138 n = 21
3.2 (2.6–4.2) 2.9 (2.3–3.7) 3.5 (2.9–4.8) 3.4 (2.8–4.9)
IC (L)
Median (IQR)
n = 306 n = 143 n = 138 n = 24
2.6 (2.1–3.4) 2.6 (2.1–3.3) 2.7 (2.1–3.5) 2.4 (2.2–3.3)
TLC (L)
Median (IQR)
n = 286 n = 128 n = 135 n = 21
6.4 (5.4–7.3) 6.0 (4.9–6.9) 6.8 (5.8–7.6) 6.5 (5.7–7.3)
RV/TLC
Median (IQR)
n = 289 n = 128 n = 138 n = 21
0.5 (0.4–0.6) 0.5 (0.4–0.6) 0.6 (0.5–0.6) 0.6 (0.5–0.6)
DLCO of the predicted (%)
Median (IQR)
n = 205 n = 98 n = 92 n = 15
68.0 (51.0–83.0) 69.5 (59.0–87.0) 63.0 (46.8–76.5) 76.7 (48.0–81.5)
mMRC Scale score n = 577 n = 334 n = 205 n = 30
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
≥ 2 (N, %) 262 (45.4) 150 (44.9) 97 (47.3) 11 (36.7)
Data about EM + CB not shown
CB Chronic Bronchitis. DLCO diffusing capacity of the lung for carbon monoxide. EM Emphysema
FEV1 forced expiratory volume in the first second. FVC forced vital capacity. IC Inspiratory capacity. IQR interquartile range. MCA Mixed-COPD asthma. mMRC
modified Medical Research Council. RV Residual Volume. SD standard deviation. TLC Total lung capacity
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early-morning and day-time symptoms, respectively)
than during night-time..
Interestingly, the proportion of subjects suffering from
night-time symptoms was higher in the CB group (53.6%)
than in the EM (39.5%) or MCA (34.4%) groups (Chi-
square test p-value presence/absence of night-time symp-
toms vs clinical phenotype = 0.0016 – see Fig. 2). In the
subsample of patients reporting night-time symptoms, the
frequency of current smokers was not significantly higher
in CB (n = 53, 28.2%) than in EM (n = 22, 25.9%) patients
(Chi-square test smoke vs clinical phenotype p-value >
0.05). In addition, the prevalence of current smokers was
unrelated to nocturnal symptoms in either CB (n = 53,
28.2% and n = 48, 29.4%, symptomatic vs asymptomaticpatients), EM (n = 22, 25.9% and n = 27, 20.8%), or CB/EM
(n = 75, 27.5% and n = 75, 25.6%).
As shown in Fig. 3a, b and c, the CB and EM phenotypes
did not differ in terms of severity of respiratory symptoms
for any portion of the 24-h day. The higher proportion of
MCA patients with severe and moderate symptoms in each
portion of the day may depend on the small sample size.
Association between circadian variability of symptoms in
each clinical phenotype and severity of disease, HR-QoL,
quality of sleep, level of physical activity and depression/
anxiety
In each clinical phenotype, the frequency of symptoms in-
creased significantly with the severity of COPD (in CB
GOLD A-D vs. presence/absence of symptoms p-values <
Table 3 Quality of life, quality of sleep, level of physical activity
and anxiety/depression at enrollment
Overall CB EM MCA
N 582 339 204 32
SGRQ symptoms score 42.5 ± 22.2 43.3 ± 22.7 40.7 ± 21.1 44.4 ± 25.3
activity score 49.8 ± 21.3 50.4 ± 21.4 49.1 ± 21.2 48.5 ± 22.1
impacts score 23.5 ± 18.7 24.0 ± 18.7 22.7 ± 18.8 22.5 ± 18.2
total score 34.5 ± 18.1 35.1 ± 18.2 33.5 ± 18.1 33.9 ± 18.5
N 597 344 213 32
CASIS total score 17.4 ± 16.2 19.3 ± 16.6 14.5 ± 14.9 14.3 ± 17.1
N 566 332 196 30
HADS Total score 9.5 ± 6.8 9.9 ± 6.9 8.9 ± 6.4 8.8 ± 7.1
Anxiety score 4.9 ± 3.7 5.1 ± 3.9 4.4 ± 3.3 4.8 ± 3.9
Depression score 4.7 ± 3.7 4.8 ± 3.6 4.5 ± 3.8 4.0 ± 3.6
N 199 113 72 11
IPAQ Level of physical activity (N, %)
Low 57 (28.6) 40 (35.4) 13 (18.1) 3 (27.3)
Moderate 139 (69.8) 72 (63.7) 57 (79.2) 8 (72.7)
High 3 (1.5) 1 (0.9) 2 (2.8) 0 (0.0)
Data about EM + CB not shown
Mean ± SD (standard deviation) were shown
CASIS COPD and Asthma Sleep Impact Scale. CB Chronic Bronchitis. EM
Emphysema. HADS Hospital Anxiety and Depression Scale. IPAQ International
Physical Activity Questionnaire. MCA Mixed-COPD asthma. SGRQ St. George’s
Respiratory Questionnaire
Fig. 2 Frequency of patients with COPD symptoms (in the week before ba
asthma. 95% confidence intervals are shown
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groups A to D with early-morning, day-time and night-
time symptoms were similar to those observed in CB, al-
though the association between GOLD classification and
symptoms was not statistically significant.
As Table 4 shows, independently of clinical phenotype,
the presence of symptoms during the 24-h day was asso-
ciated with lower QoL (T-test p-values SGRQ scores for
patients with vs. without symptoms < 0.0005) and worse
quality of sleep (T-test p-values CASIS score patients
with vs without symptoms < 0.0005).
In both the CB and EM phenotypes, mood disturbances
were significantly worse in patients with day-time and night-
time symptoms: higher HADS scores were observed, in fact,
in patients with vs. without symptoms (T-test p-values
HADS scores patients with vs. without symptoms < 0.0005).
Lastly, the level of physical activity did not differ significantly
between CB or EM patients with early-morning, day-time or
night-time symptoms and those without them (see Table 4).Discussion
The observations reported here indicate that a very high
proportion of individuals suffering from COPD and under
chronic inhaled medication nevertheless still show symp-
toms during some parts of the day. In particular, almost
80% of COPD subjects experienced symptoms during day-
time or early-morning, and half had nocturnal symptoms.
The novelty of this study is the relationship between circa-
dian rhythm of symptoms and the pre-defined clinical phe-
notypes. Night-time symptoms, alone or in combinationseline). CB: Chronic Bronchitis; EM: Emphysema; MCA: Mixed-COPD
Fig. 3 (See legend on next page.)
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Fig. 3 a Frequency of patients according to severity of night-time COPD symptoms (in the week before baseline). CB: Chronic Bronchitis; EM:
Emphysema; MCA: Mixed-COPD asthma. Percentages computed out of patients with symptoms and with non-missing severity. b Frequency of
patients according to severity of early-morning COPD symptoms (in the week before baseline). CB: Chronic Bronchitis; EM: Emphysema; MCA:
Mixed-COPD asthma. Percentages computed out of patients with symptoms and with non-missing severity. c Frequency of patients according to
severity of day-time COPD symptoms (in the week before baseline). CB: Chronic Bronchitis; EM: Emphysema; MCA: Mixed-COPD asthma.
Percentages computed out of patients with symptoms and with non-missing severity
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characterize the CB phenotype specifically.
A previous multicenter observational investigation (AS-
SESS study) was conducted in European clinical practice
centers to determine the prevalence and severity of re-
spiratory symptoms during different parts of the 24-h day
and other patient-reported outcomes (PROs) [12]. That
study found that more than half of COPD patients had
symptoms during the 24-h day, which were associated
with worse PROs; interestingly, two thirds of these pa-
tients experienced night-time symptoms. The present
study confirms and extends these observations: in a simi-
lar cohort of COPD subjects, nocturnal symptoms were
confirmed to be very common and more frequent in the
CB than in the EM phenotype. This finding advances our
knowledge on the distinctive clinical appearance of COPD
patients. Whether this is of clinical importance has yet to
be demonstrated, and future confirmatory studies are re-
quired. In both CB and EM groups, night-time symptoms
were associated with worse quality of life and quality of
sleep and higher levels of anxiety/depression.
From a clinical standpoint, there is an urgent need to
move away from the simplistic definition of COPD embra-
cing the entire spectrum of individuals with chronic, non-
reversible airway obstruction and to develop instead a
classification of subgroups on the basis of common patho-
genetic mechanisms and similar clinical manifestations.
The commonly accepted concept of COPD is well de-
scribed by the Venn diagram, which covers different clinical
phenotypes and their overlap conditions [25], in the effort
to classify COPD patients into distinct clinical manifesta-
tions, each of which requires specific treatment. In the
present study, researchers were asked for a clinical diagno-
sis of the phenotype of consecutively enrolled COPD indi-
viduals based on their judgment (according to medical
history and clinical characteristics). Chest imaging and lung
function, when available, helped to determine or confirm
the clinical decision. In this respect, the GOLD document
[11] focuses mainly on symptoms and future risk in order
to determine the proper treatment, with no distinction into
clinical phenotypes. This missing information is likely have
been a factor in the failure of large interventional clinical
trials. There is no doubt that COPD patients may respond
selectively to different treatments, depending on their
functional and clinical manifestations, and the recent lit-
erature offers evidence in support of this concept [26–29].The identification of clinical phenotypes, therefore, may
entail prognostic consequences at the individual patient
level. Since current treatment is not sufficient to control
nocturnal symptoms, specific actions are strongly advo-
cated, either a more aggressive pharmacological approach
or tests of the efficacy of non-pharmacological interven-
tions, such as pulmonary rehabilitation or non-invasive
ventilation; the latter have never been investigated and
warrant specially designed ad hoc studies.
The reasons for the greater prevalence of nighttime symp-
toms in CB individuals are unclear. Bronchial hypersecretion
and the consequent accumulation of mucus during the night
probably explains, at least in part, the more frequent occur-
rence of nocturnal symptoms. Also, the occurrence of ex-
piratory flow limitation (EFL) at night could contribute to
the respiratory symptoms. Indeed, increased bronchial vagal
hypertone, typically occurring at night, and chronic inflam-
mation and mucus, together with changes in lung volume
owing to the supine position, can favor EFL, which in turn
causes air trapping and pulmonary hyperinflation. In
addition, cough – which is the cardinal symptom of CB – is
a common cause of nocturnal awakening. On the other
hand, dyspnea is typically effort-related in mild to moderate
EM and is accordingly less severe, when the patient is at
rest. Finally, one cannot rule out report bias on the part of
EM patients. Indeed, night-time respiratory distress, by in-
creasing the abdominal pressure, might induce nicturia, and
this (rather than dyspnea) might, in turn, be perceived as the
cause of night-time awakening, along the lines of what has
been observed in elderly OSAS patients [30].
The lack of differences between the clinical phenotypes
examined with specific regard to quality of life, mood
changes and physical performance is somewhat surprising,
and it implies clinical consequences. However, the similar-
ities in terms of lung function impairment and dyspnea per-
ception may have played at least some role in explaining
the observed findings. It cannot be excluded that missing
data for each variable explored affected the outcomes. Our
present findings should improve awareness of night-time
symptoms in COPD individuals. Thus, in clinical practice
the occurrence of symptoms such as wheezing and cough-
ing during the night should be subjected to routine investi-
gation. The automated systems of long-term monitoring of
respiratory symptoms now available can record respiratory
symptoms during the nocturnal hours that would otherwise
go unnoticed [31].
Table 4 Symptoms and severity of disease, HR-QoL, quality of sleep, level of physical activity and depression/anxiety
EARLY-MORNING SYMPTOMS DAY-TIME SYMPTOMS NIGHT-TIME SYMPTOMS
No Yes p-value No Yes p-value No Yes p-value
A. CB (N = 351)
GOLD combined COPD assessment (N, %)
n 72 279 73 278 163 188
GROUP A 28 (36.8) 48 (63.2) <.0001 25 (32.9) 51 (67.1) 0.0002 52 (68.4) 24 (31.6) <.0001
GROUP B 29 (21.8) 104 (78.2) 34 (25.6) 99 (74.4) 65 (48.9) 68 (51.1)
GROUP C 6 (10.2) 53 (89.8) 8 (13.6) 51 (86.4) 24 (40.7) 35 (59.3)
GROUP D 9 (10.8) 74 (89.2) 6 (7.2) 77 (92.8) 22 (26.5) 61 (73.5)
SGRQ scores (mean ± SD)
n 71 268 71 268 159 180
symptoms 19.4 ±
16.2
49.7 ±
19.7
<.0001 18.5 ±
14.7
49.9 ±
19.6
<.0001 31.4 ±
20.3
53.9 ±
19.2
<.0001
activity 40.4 ±
17.6
53.0 ±
21.6
<.0001 39.0 ±
17.6
53.4 ±
21.4
<.0001 42.2 ±
19.0
57.6 ±
20.9
<.0001
impacts 14.6 ±
12.0
26.5 ±
19.4
<.0001 13.4 ±
12.0
26.8 ±
19.2
<.0001 15.7 ±
13.1
31.3 ±
19.9
<.0001
total 23.4 ±
12.6
38.2 ±
18.2
<.0001 22.1 ±
12.4
38.5 ±
17.9
<.0001 26.3 ±
13.8
42.9 ±
18.0
<.0001
CASIS scores (mean ± SD)
n 70 274 70 274 161 183
total 10.7 ±
12.3
21.5 ±
16.8
<.0001 9.1 ± 11.1 21.9 ±
16.7
< 0.0001 9.3 ± 9.7 28.1 ±
16.4
<.0001
HADS scores (mean ± SD)
n 69 263 69 263 156 176
total 8.3 ± 6.2 10.4 ± 7.0 0.0279 7.1 ± 5.9 10.7 ± 7.0 < 0.0001 8.0 ± 6.2 11.7 ± 7.1 < 0.0001
n 70 266 70 266 157 179
anxiety 4.4 ± 3.5 5.3 ± 4.0 > 0.05 3.8 ± 3.4 5.5 ± 4.0 0.0018 4.1 ± 3.5 6.0 ± 4.0 < 0.0001
n 69 265 69 265 156 178
depression 3.8 ± 3.0 5.1 ± 3.7 0.009 3.3 ± 3.0 5.2 ± 3.6 < 0.0001 3.9 ± 3.1 5.6 ± 3.8 < 0.0001
IPAQ Level of physical activity (N, %)
n 17 96 19 94 50 63
Low 4 (10.0) 36 (90.0) > 0.05 4 (10.0) 36 (90.0) > 0.05 19 (47.5) 21 (52.5) > 0.05
Moderate 12 (16.7) 60 (83.3) 14 (19.4) 58 (80.6) 30 (41.7) 42 (58.3)
High 1 (100.0) 0 (0) 1 (100.0) 0 (0) 1 (100.0) 0 (0)
B. EM (N = 215)
GOLD combined COPD assessment (N, %)
n 52 163 48 167 130 85
GROUP A 24 (36.4) 42 (63.6) 0.0009 23 (34.8) 43 (65.2) 0.0075 48 (72.7) 18 (27.3) 0.0035
GROUP B 14 (32.6) 29 (67.4) 10 (23.3) 33 (76.7) 22 (51.2) 21 (48.8)
GROUP C 11 (19.3) 46 (80.7) 11 (19.3) 46 (80.7) 39 (68.4) 18 (31.6)
GROUP D 3 (6.1) 46 (93.9) 4 (8.2) 45 (91.8) 21 (42.9) 28 (57.1)
SGRQ scores (mean ± SD)
n 50 154 46 158 122 82
symptoms 20.8 ±
14.7
47.1 ±
18.6
<.0001 23.7 ±
17.8
45.6 ±
19.3
<.0001 33.2 ±
18.9
51.7 ±
19.2
<.0001
activity 39.7 ±
20.8
52.2 ±
20.5
0.0003 34.8 ±
17.4
53.3 ±
20.4
<.0001 43.7 ±
18.7
57.2 ±
22.3
<.0001
impacts 13.9 ±
11.5
25.5 ±
19.9
<.0001 11.1 ± 8.7 26.0 ±
19.7
<.0001 16.1 ±
12.7
32.5 ±
22.0
<.0001
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Table 4 Symptoms and severity of disease, HR-QoL, quality of sleep, level of physical activity and depression/anxiety (Continued)
EARLY-MORNING SYMPTOMS DAY-TIME SYMPTOMS NIGHT-TIME SYMPTOMS
No Yes p-value No Yes p-value No Yes p-value
total 22.7 ±
13.0
37.0 ±
18.1
<.0001 20.3 ±
10.6
37.4 ±
18.0
<.0001 27.1 ±
13.3
43.0 ±
20.0
<.0001
CASIS scores (mean ± SD)
n 51 162 47 166 129 84
total 7.2 ± 8.2 16.8 ±
15.8
<.0001 7.1 ± 10.0 16.6 ±
15.4
< 0.0001 8.0 ± 8.7 24.6 ±
16.8
<.0001
HADS scores (mean ± SD)
n 45 151 42 154 121 75
total 6.5 ± 5.5 9.6 ± 6.5 0.0039 5.1 ± 5.1 9.9 ± 6.3 < 0.0001 7.2 ± 5.6 11.7 ± 6.6 < 0.0001
n 46 153 44 155 123 76
anxiety 3.4 ± 3.0 4.8 ± 3.3 0.0079 2.7 ± 2.4 4.9 ± 3.3 < 0.0001 3.8 ± 3.0 5.5 ± 3.5 0.0002
n 48 152 43 157 123 77
depression 3.3 ± 3.3 4.9 ± 3.9 0.0107 2.6 ± 3.2 5.0 ± 3.8 0.0002 3.4 ± 3.3 6.2 ± 3.9 < 0.0001
IPAQ Level of physical activity (N, %)
n 17 55 15 57 54 18
Low 2 (15.4) 11 (84.6) > 0.05 1 (7.7) 12 (92.3) 0.0265 8 (61.5) 5 (38.5) > 0.05
Moderate 14 (24.6) 43 (75.4) 12 (21.1) 45 (78.9) 44 (77.2) 13 (22.8)
High 1 (50.0) 1 (50.0) 2 (100.0) 0 (0) 2 (100.0) 0 (0)
The percentages of the GOLD combined COPD assessment are computed by row, i.e. over the total number of patients in Groups A, B, C, D respectively.
Similarly, the percentages of IPAQ Level of physical activity are computed by row, i.e. over the total number of patients in the low, moderate, severe
classes respectively
For SGRQ, CASIS and HADS scores T-test p-values (pts with symptoms vs. pts. without symptoms) are shown. Chi-square test p-values of GOLD combined
COPD assessment vs. presence/absence of (early-morning, day-time, night-time) symptoms are shown. Fisher exact test p-values of IPAQ Level of physical
activity vs. presence/absence of (early-morning, day-time, night-time) symptoms are shown. P-values < 0.0005 (alpha adjusted for multiple comparisons) are
in bold
CASIS COPD and Asthma Sleep Impact Scale. CB Chronic Bronchitis. EM Emphysema. HADS Hospital Anxiety and Depression Scale. IPAQ International Physical
Activity Questionnaire. SGRQ St. George’s Respiratory Questionnaire
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difference in level of physical activity, in either the
CB or the EM group, between subjects with and with-
out early-morning, day-time or night-time symptoms.
This conflicts with previous studies according to
which morning symptoms are responsible for limita-
tions of physical activity and a consequent sedentary
lifestyle [32, 33]. Differences between the tools used
to assess morning symptoms and those used to assess
the level of physical activity, as well as the items de-
rived by the latter to perform the analysis, may help
to explain the discordance between this study and
those others.
The main limitation of the present study is that the
STORICO study was not specifically designed to investi-
gate differences between clinical phenotypes, so no hy-
potheses on the proper sizes of the groups were made a
priori. As a consequence, only the CB and EM pheno-
types had a large enough sample and no conclusions
could be drawn with regard to MCA. Another limitation
is the lack of available spirometries in a minority of the
subjects enrolled. The careful evaluation of the medical
history and previous functional assessment of these sub-
jects enhanced the probability of diagnosis of COPD.Furthermore, since lung function assessment was not in-
cluded among the primary outcomes of the protocol, the
main findings of the study were not affected by it. Recall
bias could also have affected data collection: this is why
the Night-time, Morning and Day-time Symptoms of
COPD questionnaire, with its short recall period of only
1 week, was chosen to evaluate the primary objectives.
Other information was usually available in medical
charts or could be drawn from routine questionnaires
filled out during visits.Conclusions
In conclusion, the findings of this study indicate that the
circadian rhythm of symptoms can supplement the clas-
sical phenotyping of COPD patients by revealing the
prevalent phenotype-specific patterns of symptoms.
Pending a confirmatory study, these findings seem ro-
bust enough to recommend systematic assessment of
nocturnal symptoms and their correlates, mainly anxiety
and depression, in the clinical assessment of COPD pa-
tients. This would improve our knowledge of patients’
health status and, hopefully, would help to tailor COPD
therapy to the individual patient.
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